Chief Operating Officer at Glycan Therapeutics - Raleigh, North Carolina, United States
Pioneer in development of carbohydrate based drug. Our platform technology delivers structurally defined synthetic heparin scalable to replace the multibillion dollar animal based anticoagulant heparin. Our services include heparan sulfate microarray and a novel highly sensitive LC-MS based detection of heparan sulfate from body fluids and tissues.